The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study)
| Status: | Terminated |
|---|---|
| Conditions: | Parkinsons Disease |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 4/21/2016 |
| Start Date: | January 2002 |
| End Date: | March 2004 |
Unblinded, Multicenter, Prospective Follow-up of Long-term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.
To determine the long-term consequences (8 years) of initiating patients with Parkinson's
disease on either pramipexole or levodopa. We hypothesize that patients initiating therapy
with pramipexole compared with levodopa will demonstrate less self-reported disability as
measured by the Modified Schwab and England (S/E) scale 8 years after randomization.
disease on either pramipexole or levodopa. We hypothesize that patients initiating therapy
with pramipexole compared with levodopa will demonstrate less self-reported disability as
measured by the Modified Schwab and England (S/E) scale 8 years after randomization.
Inclusion Criteria:
- Available 301 subjects enrolled in the CALM-PD study.
Exclusion Criteria:
- Those not enrolled in the CALM-PD study.
We found this trial at
1
site
University of Rochester The University of Rochester is one of the country's top-tier research universities....
Click here to add this to my saved trials
